ALEXANDRIA, Va., June 16 -- United States Patent no. 12,304,952, issued on May 20, was assigned to AMGEN RESEARCH (MUNICH) GMBH (Munich).
"Antibody constructs for DLL3 and CD3" was invented by Tobias Raum (Munich), Claudia Blumel (Munich), Christoph Dahlhoff (Munich), Patrick Hoffmann (Munich), Peter Kufer (Munich), Ralf Lutterbuse (Munich), Elisabeth Nahrwold (Munich) and Jochen Pendzialek (Munich).
According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to a bispecific antibody construct comprising a first binding domain which binds to human DLL3 on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. Moreover, the invention provid...